62% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target PD-1 · moa checkpoint-inhibition-adjuvant · failure mode low-event-rate-adjuvant+monotherapy-vs-chemo
- premise dMMR colon tumors derive little benefit from fluoropyrimidine chemotherapy yet are maximally checkpoint-sensitive, and adjuvant atezolizumab added to chemotherapy improved disease-free survival in dMMR stage III colon in the ATOMIC phase 3
- premise Neoadjuvant checkpoint blockade produces near-universal major pathologic responses in dMMR colon cancer (NICHE studies), confirming that even micrometastatic dMMR disease is profoundly IO-sensitive
- premise Counterweight: here PD-1 is given as monotherapy in place of chemo rather than added to it, and adjuvant DFS endpoints with low event rates can fail to reach statistical significance even when the underlying biology favors immunotherapy
- inference Because fluoropyrimidine chemo specifically underperforms in dMMR while checkpoint blockade is maximally effective there, sintilimab plausibly improves DFS over XELOX, but the monotherapy design and event-rate risk hold this to a modest lean
- prediction 3-year DFS is met in the intended direction for the sintilimab arm with HR below 0.8